Watertown, United States
Parallel Bio is a promising startup founded in 2021, aiming to revolutionize the field of drug discovery with its innovative technology. The company has developed a groundbreaking platform described as a human 'immune system in a dish', which holds the potential to significantly improve the efficiency and effectiveness of identifying drugs and immunotherapies that have a higher likelihood of success in real patients.
Operating within the Biotechnology, Health and Wellness, Life Sciences, and Pharmaceutical industries, Parallel Bio is headquartered in the United States. This strategic positioning allows it to leverage extensive market opportunities and attract top-tier talent.
The company has successfully secured a substantial $21.00M in Series A funding as of 01 June 2025, underscoring investor confidence in its potential. As it continues its journey, the lack of disclosed investors suggests their focus remains on maintaining strategic privacy at this stage.
